TY - JOUR
T1 - Radiologic sinus inflammation and symptoms of chronic rhinosinusitis in a population-based sample
AU - Hirsch, Annemarie G.
AU - Nordberg, Cara
AU - Bandeen-Roche, Karen
AU - Tan, Bruce K.
AU - Schleimer, Robert P.
AU - Kern, Robert C.
AU - Sundaresan, Agnes
AU - Pinto, Jayant M.
AU - Kennedy, Thomas L.
AU - Greene, Joseph Scott
AU - Kuiper, Jordan R.
AU - Schwartz, Brian S.
N1 - Funding Information:
Dr Hirsch reports grants from NIAID, during the conduct of the study. Dr Bandeen‐Roche reports grants from Geisinger, during the conduct of the study, grants from National Institutes of Health, and grants from Centers for Disease Control, outside the submitted work. Dr Tan reports grants from NIH, personal fees from Optinose, and personal fees from Sanofi, outside the submitted work. Dr Schleimer reports grants from NIH, during the conduct of the study, personal fees from Intersect ENT, personal fees from GlaxoSmithKline, other from Allakos, other from AuraSense, personal fees from Merck, other from BioMarck, personal fees from Sanofi, personal fees from AstraZeneca/MedImmune, personal fees from Genentech, other from Exicure Inc, personal fees from Otsuka Inc, other from Aqualung Therapeutics Corp, personal fees from ActoBio Therapeutics, personal fees from Lyra Therapeutics, and personal fees from Astellas Pharma Inc, outside the submitted work, and in addition has a patent Siglec‐8 and Siglec‐8 ligand‐related patents licensed to Allakos Inc Dr Kern reports personal fees from Sanofi, personal fees from Novartis, personal fees from Lyra Pharmaceutical, and personal fees from Neurent, outside the submitted work. Dr Sundaresan reports grants from NIH, during the conduct of the study. Dr Pinto reports personal fees from Optinose, personal fees from Genentech, personal fees from ALK, personal fees from Stallergenes, and grants from NIH, outside the submitted work. Dr Kennedy, Dr Greene, and Dr Kuiper have nothing to disclose. Dr Schwartz reports grants from NIAID, during the conduct of the study.
Funding Information:
This work was supported by The National Institutes of Health [U19AI106683]. We thank Dione Mercer, Jacob Mowery, and Caroline Price for coordinating the recruitment, collection, and scoring of sinus CT scans.
Publisher Copyright:
© 2019 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
PY - 2020/4/1
Y1 - 2020/4/1
N2 - Background: Chronic rhinosinusitis (CRS) epidemiology has been largely studied using symptom-based case definitions, without assessment of objective sinus findings. Objective: To describe radiologic sinus opacification and the prevalence of CRS, defined by the co-occurrence of symptoms and sinus opacification, in a general population-based sample. Methods: We collected questionnaires and sinus CT scans from 646 participants selected from a source population of 200 769 primary care patients. Symptom status (CRSS) was based on guideline criteria, and objective radiologic inflammation (CRSO) was based on the Lund-Mackay (L-M) score using multiple L-M thresholds for positivity. Participants with symptoms and radiologic inflammation were classified as CRSS+O. We performed negative binomial regression to assess factors associated with L-M score and logistic regression to evaluate factors associated with CRSS+O. Using weighted analysis, we calculated estimates for the source population. Results: The proportion of women with L-M scores ≥ 3, 4, or 6 (CRSO) was 11.1%, 9.9%, and 5.7%, respectively, and 16.1%, 14.6%, and 8.7% among men. The respective proportion with CRSS+O was 1.7%, 1.6%, and 0.45% among women and 8.8%, 7.5%, and 3.6% among men. Men had higher odds of CRSS+O compared to women. A greater proportion of men (vs women) had any opacification in the frontal, anterior ethmoid, and sphenoid sinuses. Conclusion: In a general population-based sample in Pennsylvania, sinus opacification was more common among men than in women and opacification occurred in different locations by sex. Male sex, migraine headache, and prior sinus surgery were associated with higher odds of CRSS+O.
AB - Background: Chronic rhinosinusitis (CRS) epidemiology has been largely studied using symptom-based case definitions, without assessment of objective sinus findings. Objective: To describe radiologic sinus opacification and the prevalence of CRS, defined by the co-occurrence of symptoms and sinus opacification, in a general population-based sample. Methods: We collected questionnaires and sinus CT scans from 646 participants selected from a source population of 200 769 primary care patients. Symptom status (CRSS) was based on guideline criteria, and objective radiologic inflammation (CRSO) was based on the Lund-Mackay (L-M) score using multiple L-M thresholds for positivity. Participants with symptoms and radiologic inflammation were classified as CRSS+O. We performed negative binomial regression to assess factors associated with L-M score and logistic regression to evaluate factors associated with CRSS+O. Using weighted analysis, we calculated estimates for the source population. Results: The proportion of women with L-M scores ≥ 3, 4, or 6 (CRSO) was 11.1%, 9.9%, and 5.7%, respectively, and 16.1%, 14.6%, and 8.7% among men. The respective proportion with CRSS+O was 1.7%, 1.6%, and 0.45% among women and 8.8%, 7.5%, and 3.6% among men. Men had higher odds of CRSS+O compared to women. A greater proportion of men (vs women) had any opacification in the frontal, anterior ethmoid, and sphenoid sinuses. Conclusion: In a general population-based sample in Pennsylvania, sinus opacification was more common among men than in women and opacification occurred in different locations by sex. Male sex, migraine headache, and prior sinus surgery were associated with higher odds of CRSS+O.
KW - CT scan
KW - chronic rhinosinusitis
KW - epidemiology
KW - sex
KW - sinus
UR - http://www.scopus.com/inward/record.url?scp=85076190803&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076190803&partnerID=8YFLogxK
U2 - 10.1111/all.14106
DO - 10.1111/all.14106
M3 - Article
C2 - 31713250
AN - SCOPUS:85076190803
SN - 0105-4538
VL - 75
SP - 911
EP - 920
JO - Acta Allergologica
JF - Acta Allergologica
IS - 4
ER -